Datopotamab Deruxtecan 治疗晚期或转移性 HR+/HER2- 及三阴性乳腺癌:I 期 TROPION-PanTumor01 研究结果
TROPION-PanTumor01 是一项 I 期剂量递增和剂量扩展研究,评估 Datopotamab deruxtecan(Dato-DXd)在经治实体瘤患者中的安全性和耐受性。截至 2022 年 7 月 22 日,85 例晚期/转移性乳腺癌患者(HR+/HER2- 41 例,三阴性 44 例)接受 Dato-DXd 治疗,HR+/HER2- 和三阴性乳腺癌的客观缓解率分别为 26.8% 和 31.8%,中位无进展生存期分别为 8.3 个月和 4.4 个月。
要点
- Dato-DXd 在重度经治的晚期 HR+/HER2- 和三阴性乳腺癌中显示出有前景的临床活性。
- HR+/HER2- 乳腺癌客观缓解率 26.8%(95% CI 14.2–42.9),三阴性乳腺癌 31.8%(95% CI 18.6–47.6)。
- 安全性总体可控,口腔炎是最常见治疗中出现的不良事件。
核心结论
- 在重度经治的晚期 HR+/HER2- 乳腺癌和三阴性乳腺癌患者中,Dato-DXd 显示出有前景的临床活性和可控的安全性。
- Dato-DXd 目前正在 III 期研究中进行评估。
研究设计与样本
- TROPION-PanTumor01(ClinicalTrials.gov 标识号 NCT03401385)是一项 I 期剂量递增和剂量扩展研究,评估 Dato-DXd 在经治实体瘤患者中的安全性和耐受性。
- 主要研究目标为评估 Dato-DXd 的安全性和耐受性,次要目标包括评估抗肿瘤活性和药代动力学。
- 报告了晚期/转移性激素受体阳性/人表皮生长因子受体 2 阴性(HR+/HER2-)乳腺癌或三阴性乳腺癌(TNBC)患者的结果。
- 数据截止日期为 2022 年 7 月 22 日,共 85 例患者接受 Dato-DXd 治疗(HR+/HER2- 乳腺癌 41 例,TNBC 44 例)。
主要发现
- 经盲态独立中心审查,HR+/HER2- 乳腺癌患者的客观缓解率为 26.8%(95% CI 14.2–42.9),TNBC 患者为 31.8%(95% CI 18.6–47.6)。
- HR+/HER2- 乳腺癌队列的中位缓解持续时间不可评估,TNBC 队列为 16.8 个月。
- HR+/HER2- 乳腺癌和 TNBC 患者的中位无进展生存期分别为 8.3 个月和 4.4 个月。
- HR+/HER2- 乳腺癌患者中,任何级别和 ≥3 级全因治疗中出现的不良事件(TEAE)发生率分别为 100% 和 41.5%;TNBC 患者分别为 100% 和 52.3%。
- HR+/HER2- 乳腺癌队列中最常见的 TEAE 为口腔炎(任何级别 82.9%,≥3 级 9.8%),TNBC 队列中为口腔炎(任何级别 72.7%,≥3 级 11.4%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker. PATIENTS AND METHODS: TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors. The primary study objective was to assess the safety and tolerability of Dato-DXd. Secondary objectives included evaluation of antitumor activity and pharmacokinetics. Results from patients with advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC) or triple-negative BC (TNBC) are reported. RESULTS: At data cutoff (July 22, 2022), 85 patients (HR+/HER2- BC = 41, and TNBC = 44) had received Dato-DXd. The objective response rate by blinded independent central review was 26.8% (95% CI, 14.2 to 42.9) and 31.8% (95% CI, 18.6 to 47.6) for patients with HR+/HER2- BC and TNBC, respectively. The median duration of response was not evaluable in the HR+/HER2- BC cohort and 16.8 months in the TNBC cohort. The median progression-free survival in patients with HR+/HER2- BC and TNBC was 8.3 and 4.4 months, respectively. All-cause treatment-emergent adverse events (TEAEs; any grade, grade ≥3) were observed in 100% and 41.5% of patients with HR+/HER2- BC and 100% and 52.3% of patients with TNBC. Stomatitis was the most common TEAE (any grade, grade ≥3) in both HR+/HER2- BC (82.9%, 9.8%) and TNBC (72.7%, 11.4%) cohorts. CONCLUSION: In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.
引用
- Bardia A, Krop IE, Kogawa T, et al. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024. PMID: 38652877. doi:10.1200/JCO.23.01909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。